233 research outputs found
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Background Patients with rheumatoid arthritis (RA), including those treated
with biologics, are at increased risk of some vaccine-preventable infections.
We evaluated the antibody response to standard 23-valent pneumococcal
polysaccharide vaccine (PPSV23) and the 2011ā2012 trivalent seasonal influenza
vaccine in adults with RA receiving subcutaneous (SC) abatacept and background
disease-modifying anti-rheumatic drugs (DMARDs). Methods Two multicenter,
open-label sub-studies enrolled patients from the ACQUIRE (pneumococcal and
influenza) and ATTUNE (pneumococcal) studies at any point during their SC
abatacept treatment cycle following completion of ā„3 monthsā SC abatacept. All
patients received fixed-dose abatacept 125 mg/week with background DMARDs. A
pre-vaccination blood sample was taken, and after 28āĀ±ā3 days a final post-
vaccination sample was collected. The primary endpoint was the proportion of
patients achieving an immunologic response to the vaccine at Day 28 among
patients without a protective antibody level to the vaccine antigens at
baseline (pneumococcal: defined as ā„2-fold increase in post-vaccination titers
to ā„3 of 5 antigens and protective antibody level of ā„1.6 Ī¼g/mL to ā„3 of 5
antigens; influenza: defined as ā„4-fold increase in post-vaccination titers to
ā„2 of 3 antigens and protective antibody level of ā„1:40 to ā„2 of 3 antigens).
Safety and tolerability were evaluated throughout the sub-studies. Results
Pre- and post-vaccination titers were available for 113/125 and 186/191
enrolled patients receiving the PPSV23 and influenza vaccine, respectively.
Among vaccinated patients, 47/113 pneumococcal and 121/186 influenza patients
were without protective antibody levels at baseline. Among patients with
available data, 73.9 % (34/46) and 61.3 % (73/119) met the primary endpoint
and achieved an immunologic response to PPSV23 or influenza vaccine,
respectively. In patients with pre- and post-vaccination data available, 83.9
% in the pneumococcal study demonstrated protective antibody levels with
PPSV23 (titer ā„1.6 Ī¼g/mL to ā„3 of 5 antigens), and 81.2 % in the influenza
study achieved protective antibody levels (titer ā„1:40 to ā„2 of 3 antigens) at
Day 28 post-vaccination. Vaccines were well tolerated with SC abatacept with
background DMARDs. Conclusions In these sub-studies, patients with RA
receiving SC abatacept and background DMARDs were able to mount an appropriate
immune response to pneumococcal and influenza vaccines. Trial registration
NCT00559585 (registered 15 November 2007) and NCT00663702 (registered 18 April
2008)
Recommended from our members
Enhanced reactivity to pain in patients with rheumatoid arthritis
Introduction: Maladaptive physiological responses to stress appear to play a role in chronic inflammatory diseases such as rheumatoid arthritis (RA). However, relatively little stress research in RA patients has involved the study of pain, the most commonly reported and most impairing stressor in RA. In the present study, we compared psychophysical and physiological responses to standardized noxious stimulation in 19 RA patients and 21 healthy controls. Methods: Participants underwent a single psychophysical testing session in which responses to a variety of painful stimuli were recorded, and blood samples were taken at multiple time points to evaluate the reactivity of cortisol, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-Ī±) to the experience of acute pain. Results: The findings suggest that RA patients display a fairly general hyperalgesia to mechanical and thermal stimuli across several body sites. In addition, while serum cortisol levels did not differ at baseline or following pain testing in patients relative to controls, the RA patients tended to show elevations in serum IL-6 and demonstrated enhanced pain-reactivity of serum levels of TNF-Ī± compared with the healthy controls (P < 0.05). Conclusions: These findings highlight the importance of pain as a stressor in RA patients and add to a small body of literature documenting amplified responses to pain in RA. Future studies of the pathophysiology of RA would benefit from the consideration of acute pain levels when comparing RA patients with other groups, and future trials of analgesic interventions in RA patients may benefit from evaluating the effects of such interventions on inflammatory activity
Recommended from our members
Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis
Background: Defining environmental factors responsible for development of autoimmunity in rheumatoid arthritis (RA) is critical for understanding mechanisms of disease initiation and propagation. Notably, a history of cigarette smoking has been implicated in the genesis of RA and is associated with worse disease outcomes. Antibodies to peptidylarginine deiminase 4 (PAD4) are also associated with more severe RA. A subset of patients who have PAD4 autoantibodies that cross-react with PAD3 (anti-PAD3/4) are at the highest risk for interstitial lung disease, and this risk is augmented by a history of cigarette smoking. It is unclear, however, if smoking is etiologically linked to the development of anti-PAD4 antibodies. Methods: Patients were included in this study if they had physician-diagnosed RA as well as DNA, serum, and a date-matched clinical assessment (n = 274). Anti-PAD4 and anti-CCP antibodies were measured by immunoprecipitation and ELISA, respectively; shared epitope (SE) status was determined by HLA-DRĪ²1 genotyping. Logistic regression analysis was used to evaluate associations of smoking with PAD4 antibodies, with adjustment for relevant demographic and clinical features. Stratified analyses by disease duration and shared epitope status were also performed. Results: Anti-PAD4 antibodies were present in 25% of RA patients, with 50% of these individuals having anti-PAD3/4 cross-reactive antibodies. Anti-PAD4 antibodies were significantly associated with a longer disease duration, SE alleles, and anti-CCP antibodies. Importantly, there were no significant differences in smoking history between anti-PAD4 positive and negative groups in univariate analyses, stratified analyses, or multivariable models. However, an inverse relationship between smoking and anti-PAD4 antibodies was suggested by a lower prevalence of current smokers among patients with anti-PAD3/4 antibodies compared to antibody negative individuals (p = 0.04). Further, the lowest levels of anti-PAD4 antibodies were observed in current smokers (p = 0.14), and a significant association of SE and anti-PAD4 antibodies was only present among never smokers (p = 0.01). Conclusions: Smoking history was not associated with anti-PAD4 antibodies in patients with RA. The finding that anti-PAD4 antibodies were not associated with smoking suggests that other environmental factors may contribute to the development of autoimmunity to PAD4 in these patients
- ā¦